Trends in early initiation of antiretroviral therapy and characteristics of persons with HIV initiating therapy in San Francisco, 2007-2011

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1310-1314

  Hsu, Ling Chin ^a   Truong, Hong Ha M ^b   Vittinghoff, Eric ^b   Zhi, Qi ^a   Scheer, Susan ^a   Schwarcz, Sandra ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral therapy; ART initiation; CD4; HIV

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE SURVEILLANCE; FEMALE; HEALTH CARE POLICY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; PUBLIC HEALTH; TIME TO TREATMENT; TREND STUDY; UNITED STATES; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; ART INITIATION; CD4; HIV;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SAN FRANCISCO; YOUNG ADULT;

EID: 84898880447     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit599     Document Type: Article

References (15)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-29
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+cell strata. Ann Intern Med 2003; 138:620-6
3. Strategies for Management of Antiretroviral Therapy (SMART) Study GroupEmery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-44
4. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26
5. When to Start ConsortiumSterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2012. http://www. aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL003093.pdf. Accessed 17 July 2013
7. Russell R. City endorses new policy for treatment of HIV. The New York Times. 3 April 2010. http://www.nytimes.com/2010/04/04/ us/04sftreatment.html. Accessed 7 February 2013
8. Jain V, Deeks SG. When to start antiretroviral therapy. Curr HIV/AIDS Rep 2010; 7:60-8
9. San Francisco Department of Public Health, HIV Epidemiology Section. HIV/AIDS epidemiology annual report 2011. Published August 2012. http://www.sfdph.org/dph/comupg/oprograms/hivepisec/ default.asp. Accessed 17 December 2012
10. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:701-6
11. Dickson-Gomez J, McAuliffe T, Convey M, Weeks M, Owczarzak J. Access to housing subsidies, housing status, drug use and HIV risk among low-income U.S. urban residents. Subst Abuse Treat Prev Policy 2011; 6:31
12. Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks HS. Aging and HIV infection. J Urban Health 2006; 83:31-42
13. Hsu LC, Vittinghoff E, Katz M, et al. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001; 28: 345-50
14. Scheer S, Chu P, Vittinghoff E, Colfax G, Das M. Significant reductions in time to virologic suppression and disparities in suppression rates: San Francisco, 2004-2010. Abstract 1071. In: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 5-8 March 2012
15. Geng EH, Hare CB, Kahn JO, et al. The effect of a universal antiretroviral therapy recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/uL in a public health setting. Clin Infect Dis 2012; 55:1690-7.